Anavex Life Sciences (AVXL)
(Delayed Data from NSDQ)
$5.15 USD
-0.41 (-7.37%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $5.14 -0.01 (-0.19%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
Anavex Life Sciences Corp. [AVXL]
Reports for Purchase
Showing records 21 - 40 ( 159 total )
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Preclinical Data Suggest ANAVEX3-71 Anti-Alzheimer''s Impact; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: ANAVEX 3-71 for Prevention in Alzheimer''s Disease
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex?s P2b/3 Trial of ANAVEX2-73 in Alzheimer?s Disease Shows Robust Clinical Efficacy and Slows Neurodegeneration
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F3Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Fiscal 1Q Results: $155M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
ANAVEX3-71 Study Publication; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Dual Mechanisms in Alzheimer''s Bode Well for Blarcamesine; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Potential Disease-Modifying Impact in Rett Syndrome; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: 2-73 Shows a Disease Modifying Effect in Rett?s Patients
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Additional IP to 2036 Helps Secure Valuation
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Completion of ANAVEX?2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Rett Syndrome Data Release Approaching; F2Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Reports the Quarter - $153M in Cash and Equivalents - Looking at Accelerated Pathway for Alzheimer?s
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
New Blarcamesine Patent Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
Blarcamesine Shows Long-Term Parkinson''s Disease Benefit; Raising PT to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Anavex 2-73 Shows Long-Term Benefit in Parkinson?s Disease Dementia Going Pivotal Now
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Hires Ex-FDA Biostatistician CNS Expert
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
F1Q23 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
BUY Rated: Reports Fiscal 1st QTR: $15M Burn, $143M in Cash
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Anavex Life Sciences Corp.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department